First-Line Zongertinib in Advanced HER2-Mutant NSCLC: A New Targeted Standard Begins to Take Shape

oncodaily - For years, HER2-mutant non-small-cell lung cancer sat in an uncomfortable place in thoracic oncology. It was clearly an oncogene-driven disease, but unlike EGFR-mutant or ALK-rearranged NSCLC, it did not have […]

AI Summary: Clinical trial data show zongertinib delivers strong antitumor activity as a first‑line treatment for patients with advanced HER2‑mutant non‑small cell lung cancer, positioning the drug as a potential new targeted standard. Robust response rates in previously untreated patients are prompting clinicians to rethink initial treatment choices while attention turns to long‑term safety and access.

Eating more fruits and vegetables tied to unexpected lung cancer risk

sciencedaily - A surprising new study suggests that eating a very healthy diet—packed with fruits, vegetables, and whole grains—might be linked to a higher risk of lung cancer in younger non-smokers. Researchers found that patients under 50 diagnosed with lung cancer of…

AI Summary: A new analysis links higher fruit-and-vegetable consumption to an unexpected rise in lung cancer risk among younger non‑smokers, with investigators pointing to pesticide residues on produce as a likely culprit. Researchers urge careful interpretation—don’t ditch your salad—while calling for stricter residue limits, better monitoring, and further study to untangle diet, toxins, and cancer risk.

Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors

Frank Vinluan / medcitynews - Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better efficacy, CrossBio’s dual approach could also fight drug resistance. The post El…

AI Summary: Eli Lilly agreed to acquire CrossBridge Bio for up to $300 million, adding small‑molecule oncology assets to its pipeline. The deal accelerates Lilly’s tumor‑targeting strategy, reflects Big Pharma’s preference for buying nimble biotech innovation, and highlights ongoing consolidation trends that determine where promising oncology programs ultimately end up.

ESMO 2026 Guideline: Redefining the Management of Metastatic Colorectal Cancer

oncodaily - Metastatic colorectal cancer (mCRC) represents a complex and biologically diverse disease in which treatment decisions increasingly depend on molecular characteristics, disease burden, and patient-specific factors. While therapeutic options have expanded …

AI Summary: The European Society for Medical Oncology released updated clinical practice guidelines for metastatic colorectal cancer, redefining diagnostic pathways, systemic therapy sequencing, and follow‑up standards. The guidance incorporates recent targeted and immunotherapy evidence to recommend practical treatment algorithms, prompting oncology centers to update protocols and payers to reassess coverage as clinicians translate recommendations into routine care.

Gilead Activates Its Pipeline: Option Exercises at Cartography Bio and Kymera Signal Accelerating Oncology Execution

oncodaily - In a pair of announcements that underscore Gilead Sciences’ intensifying commitment to oncology, two of its collaboration partners, Cartography Biosciences and Kymera Therapeutics, revealed today that Gilead has exercised exclusive […]

AI Summary: Gilead moved to accelerate its oncology strategy by exercising option agreements with smaller biotech partners, including Kymera and Cartography Bio. The moves signal targeted investment in protein degraders and other novel modalities, shoring up the company’s mid‑stage pipeline and hinting that big pharma still prefers buying options to inventing overnight.

Oricell Lands $110M to Take Cell Therapy to New Territory in Cancer

Frank Vinluan / medcitynews - There are no FDA-approved therapies for GPC3, a protein highly expressed by liver cancers. Oricell Therapeutics claims its cell therapy could be best in this class, but it faces competition from companies such as AstraZeneca and Eureka Therapeutics. The p…

AI Summary: Oricell, a China‑based CAR‑T developer, secured fresh financing to accelerate its cell‑therapy programs and support plans to go public. The fundraising will bankroll clinical expansion, manufacturing scale‑up, and regulatory preparations as the company pushes toward broader development and an IPO ambition, positioning it to compete in the crowded CAR‑T market.

FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer

esmo - Evidence for efficacy is based on the findings from the ROSELLA study

AI Summary: The FDA granted marketing authorization for relacorilant in combination with nab‑paclitaxel to treat platinum‑resistant epithelial ovarian, fallopian tube and primary peritoneal cancers. Regulators cited clinical benefit in a difficult‑to‑treat population, providing an additional therapeutic option for patients with limited choices and marking an important regulatory milestone.

James P. Allison, PhD, FAACR, Honored With the 2026 AACR Award for Lifetime Achievement in Cancer Research

oncodaily - James P. Allison has been honored with the 2026 AACR Award for Lifetime Achievement in Cancer Research, a distinction recognizing his extraordinary scientific achievements and enduring impact on modern oncology. […]

AI Summary: James P. Allison received the 2026 AACR Award for Lifetime Achievement in Cancer Research for pioneering work in cancer immunotherapy. The award recognizes decades of transformative science that helped establish immune‑checkpoint blockade as a foundational cancer treatment, altering therapeutic strategies across multiple tumor types.

Antoni Ribas, MD, PhD, FAACR, Honored With the 2026 AACR-Margaret Foti Award

oncodaily - The American Association for Cancer Research (AACR) has named Antoni Ribas as the recipient of the 2026 AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research, recognizing a […]

AI Summary: Antoni Ribas was honored with the AACR‑Margaret Foti Award in recognition of leadership and major contributions to cancer research. The award spotlights Ribas’ influence on immunotherapy development and cancer science translation, celebrating a career that has shaped both scientific agendas and clinical practice.

Gilead continues dealmaking streak with $3.15B Tubulis buy for ADCs

Kyle LaHucik / endpoints - In its third acquisition of 2026, Gilead is spending $3.15 billion upfront to snag a next-generation antibody-drug conjugate platform from German startup Tubulis. The California biopharma could pay out another $1.85 billion down the road ...

AI Summary: Gilead Sciences struck a multibillion-dollar acquisition to add Tubulis and bolster its oncology pipeline, buying into antibody-drug conjugate technology. The deal signals Gilead’s strategic pivot to expand beyond infectious disease into cancer therapeutics, accelerating access to novel modalities and reshaping competitive dynamics in biopharma.

Uveal Melanoma: ESMO–EURACAN Clinical Practice Guideline

esmo - This ESMO–EURACAN CPG provides key recommendations for the diagnosis, staging, treatment and follow-up for uveal melanoma. It includes percutaneous hepatic perfusion and tebentafusp as treatment options for metastatic disease, reflecting emerging evidence…

AI Summary: ESMO–EURACAN released a comprehensive clinical practice guideline for uveal melanoma covering diagnosis, staging, surveillance and systemic management. The guidance clarifies best practices for multidisciplinary care, risk stratification and therapeutic sequencing, aiming to standardize treatment and follow‑up for a rare but high‑risk ocular tumour.

Bowelbabe Fund celebrates raising £20m by announcing the Bowelbabe Vaccine

Sophie Wedekind / cancerresearchuk - The Bowelbabe Fund has raised more that £20 million and has announced the next wave of funded projects, including the Bowelbabe Vaccine.The post Bowelbabe Fund celebrates raising £20m by announcing the Bowelbabe Vaccine appeared first on Cancer Research U…

AI Summary: The Bowelbabe Fund celebrated a £20 million fundraising milestone and unveiled plans for a Bowelbabe Vaccine initiative, drawing high‑profile support. Organizers framed the cash infusion as a catalyst for prevention and research efforts, while public endorsements highlighted momentum — and the fundraising thermometer that finally stopped making them blush.

Targeted, High-dose Radiation May Improve Treatment for ‘Supermassive’ Bile Duct Tumors

Kathleen Medora / aacr - Patients with very large intrahepatic cholangiocarcinoma experienced improved outcomes when targeted, high-dose radiation was added to chemotherapy PHILADELPHIA – Patients with supermassive intrahepatic cholangiocarcinoma (ICC) benefited from ablative rad…

AI Summary: New clinical reports indicate that targeted high‑dose radiation can improve outcomes for very large “supermassive” bile duct tumors, offering better local control and symptom relief than conventional approaches. Early data suggest this intensity‑modulated strategy may expand options for otherwise difficult‑to‑treat cases, though longer follow‑up is needed to confirm survival benefits.